electroCore (ECOR) risk factors, FY2024 10-K

Risk Related to our Financial Position, Operating Results and Need for Additional Capital

1. 01We may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all
2. 02the emergence and acceptance of competing therapies or other adverse market developments
3. 03We launched new cash pay initiatives, including our gConcierge and gCDirect programs, as well as our direct-to-consumer business channel and patients, providers or consumers may be slow to adopt these programs or their pricing which could adversely impact our business and financial results
4. 04If third-party payors do not provide adequate coverage and reimbursement for the use of gammaCore, it may affect our ability to generate significant revenues
5. 05We have a limited history commercializing our nVNS platform technology, including through direct-to-consumer channels, and commercial success is uncertain
6. 06We have a limited history commercializing our general wellness and human performance products in the United States for which market acceptance and commercial success are uncertain
7. 07We recently launched our next generation app-enabled consumer wellness product under the brand Truvaga and there can be no assurance that the new product will continue to be well received or adopted, which may impact our financial results
8. 08Our next generation app-enabled consumer wellness product may require modifications and improvements, which may cause added expense and negatively impact our financial results
9. 09We generate sales of TAC-STIM branded products to active-duty military and accordingly, military budgetary cuts or government strikes could negatively impact our financial results
10. 10Unfavorable global economic conditions and government regulations could adversely affect our business, financial condition or results of operations
11. 11We have limited operating experience at our current scale of operations. If we are unable to manage our growth effectively, our brand, company culture, and financial performance may suffer
12. 12Any significant disruption to our ecommerce business could result in lost sales
13. 13We are subject to increasing operating costs and inflation risks, which may adversely affect our performance
14. 14We must successfully attract, hire, train, and retain qualified professionals to service our direct-to-consumer sales channels, and we must productively deploy our professionals to become profitable
15. 15Our consultants and certain of our sales force are classified as independent contractors, and we can face consequences if it is determined that they are misclassified as such
16. 16If we experience price fluctuations for our products, and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, and financial condition
17. 17Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price
18. 18Future acquisitions, including the recently announced acquisition of NURO, strategic investments, or alliances could disrupt our business and harm our business, financial condition, and operating results
19. 19litigation or other claims in connection with the acquired company, including claims from terminated employees, users, former stockholders or third parties
20. 20The closing of our acquisition of NURO is subject to customary closing conditions, and there can be no assurance that NURO will meet the closing conditions, and failure to close the transaction may harm our business and cause our stock price to fall
21. 21Unanticipated costs relating to our acquisition of NURO could have an adverse impact on our business, financial condition, and operating results
22. 22We may not be able to fully realize the benefits from the NURO Transaction
23. 23Litigation may arise in connection with our acquisition of NURO, which could be costly, prevent consummation of the transaction, divert management’s attention, and otherwise harm our business, financial condition, and results of operations
24. 24Closing down the DPNCheck business may be costly and provide additional regulatory scrutiny

Risks Related to Our Business

1. 25Regulatory requirements and changes to payors’ prescription benefit plans and medical pathway plans could adversely impact our business and financial results
2. 26Our commercialization strategy of gammaCore may expose us to increased billing, cash application, and credit risks
3. 27Third-party payors have been resistant to cover gammaCore through pharmacy benefit plans, which has hindered our commercialization strategy and required changes to our existing business that could delay and negatively impact our ability to generate revenue
4. 28We must demonstrate to patients, physicians, and third-party payors the medical and economic benefits of our prescription gammaCore therapy compared to those of our competitors or other available therapies, and such comparisons may not be realizable
5. 29We must demonstrate to customers the benefits of nVNS platform technology for general wellness and human performance compared to those of our competitors and such comparisons may not be realizable
6. 30Stimulating therapeutically relevant fibers in the vagus nerve by a proprietary high-frequency burst waveform that passes through the skin cells represents a novel approach to treating pain, and we must overcome significant challenges to successfully develop, commercialize, and manufacture our product
7. 31Our operating results may vary significantly from quarter to quarter because of seasonality, bulk orders, shipments to distributors, or otherwise
8. 32the timing of customer budget cycles
9. 33We derive a material portion of our revenue from a limited number of customers, and the loss of one or more of these customers could adversely impact our business, results of operations, and financial condition
10. 34We currently generate a small portion of our revenue through distribution of other manufacturers products through our government sales channel, and any issue arising from these products may impact our relationship with the Veterans Administration resulting in negative impact to our business
11. 35We currently distribute products manufactured by other companies. Any disruption in our supply chain, or our failure to successfully manage our relationships with our suppliers could harm our business
12. 36Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results
13. 37We may engage in future acquisitions that increase our capital requirements, dilute our stockholders, cause us to incur debt, or assume contingent liabilities that subject us to other risks
14. 38Any clinical trial we conduct in the United States may subject us to additional costs and detriments compared to a foreign clinical trial, which may negatively impact our financial condition and our business
15. 39If we are unable to enroll patients in future clinical trials, our research and development efforts could be adversely affected
16. 40the proximity and availability of clinical trial sites for prospective patients
17. 41Clinical trials may be delayed, suspended, or terminated for many reasons, which will increase our expenses and delay the time it takes to develop and expand our prescription gammaCore therapy in additional treatment indications
18. 42Consistent with recent years, we continue not to invest in certain clinical trials in indications that are more exploratory in nature
19. 43Our cost-control efforts might not assure profitability and may affect morale and make it difficult to retain employees, independent contractors, or attract new ones
20. 44We have outsourced certain finance and accounting functions and may outsource other back-office functions, which will make us more dependent upon third parties
21. 45If we fail to properly manage our anticipated growth, our business could suffer
22. 46Future growth will also impose significant added responsibilities on management, including the need to identify, recruit, train, or integrate new businesses and additional employees. In addition, rapid and significant growth will place a strain on our administrative and operational infrastructure
23. 47If we fail to continue to develop and retain an effective sales force, our business could suffer
24. 48If our competitors are better able to develop and market primary headache treatments that are safer, more effective, less costly, easier to use, or otherwise more attractive than our prescription gammaCore therapy, our business and business prospects will be adversely impacted
25. 49greater experience in and resources for conducting research and development, clinical studies, manufacturing, preparing regulatory submissions, obtaining regulatory clearance or approval for products and marketing approved products
26. 50Many of our competitors are large, well-established companies with substantially greater resources than us and have a long history of competing in the migraine or general wellness markets
27. 51We may expend our limited resources to pursue a particular product candidate or disease and fail to capitalize on product candidates or diseases that may be more profitable or for which there is a greater likelihood of success
28. 52Our international operations subject us to certain operating and compliance risks, which could adversely impact our results of operations and financial condition
29. 53the imposition of new trade restrictions; and
30. 54Our results may be impacted by changes in foreign currency exchange rates
31. 55We may not be able to establish or strengthen our brands
32. 56We may face product liability claims that could result in costly litigation and significant liabilities
33. 57a decline in our stock price
34. 58Our operating results and profitability may be adversely affected by increases in reserves for product returns, doubtful accounts receivable, and inventory
35. 59If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, or if third-party payors were to deny claims, additional provisions for doubtful accounts may be required
36. 60If we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel
37. 61If we are unable to retain or attract the independent contractors in our sales force, our sales efforts may be adversely impacted
38. 62We may be held responsible for certain taxes or assessments and other obligations relating to the activities of our independent contractors, which could harm our financial condition and operating results
39. 63Our future success depends on our leadership development and succession planning
40. 64Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
41. 65The increasing use of social media could give rise to liability

Risks Related to our Dependence on Third Parties

1. 66We have signed a distribution agreement with Lovell to sell certain gammaCore products throughout the government channel through Lovell’s contract vehicles, and we may therefore be dependent on Lovell
2. 67We are offering products to government customers through two different contracting vehicles, which may cause confusion for purchasing agents and result in frustration by customers
3. 68We have signed a distribution agreement with Joerns Healthcare (“Joerns”) to sell certain gammaCore products throughout certain managed healthcare systems through the Joerns contract vehicles which puts a significant dependence on Joerns
4. 69Our new app-enabled consumer product relies on third-party vendors for application development and management which puts a significant dependency on the third-party vendor
5. 70We have limited experience with the supply chain of our next generation app-enabled consumer general wellness product under the brand Truvaga and are dependent on third parties for related software development
6. 71We have limited experience with the supply chain of our human performance product under the brand TAC-STIM and are dependent on third parties for related software development
7. 72Outside the United States, we rely on a single third-party distributor to effectively distribute the majority of our products
8. 73Our status as a supplier to the federal government subjects us to a wide variety of regulatory compliance, pricing, and contract-based requirements. Failure to comply with these requirements could adversely impact our ability to obtain future federal contracts, which could negatively impact us and our business
9. 74Our potential revenue in the United Kingdom is substantially dependent on government funding arrangements, and changes in governmental policy for such arrangements could cause material harm to our business
10. 75We rely on third parties to conduct and support clinical trials and investigator - initiated trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials
11. 76Additionally, patient enrollment is affected by many factors beyond our control and the control of the third parties upon whom we rely to conduct IITs. As a result, we cannot predict how successful our IITs will be at enrolling patients
12. 77If we do not successfully enter into future collaborations for the development, regulatory clearance, and commercialization of our prescription gammaCore therapy in international markets, our business may be harmed
13. 78collaborators may own or co-own intellectual property covering our products that result from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property
14. 79If we are not able to establish or maintain collaborations, we may have to alter some of our future development, regulatory clearance, and commercialization plans
15. 80In order to commercialize products, we, or our manufacturers, will need to manufacture products in large quantities
16. 81Our nVNS technology platform consists of a substantial number of individual components. In order to market and sell effectively, we often must maintain high levels of inventory of the product and its components

Risks Related to Intellectual Property

1. 82Our product development initiatives may be delayed or fail to succeed and could also lead to challenging intellectual property rights issues
2. 83The markets in which we compete and expect to compete are subject to rapid technological change and frequent litigation regarding patent and other intellectual property rights. It is possible that our patents or licenses may not withstand challenges made by others or protect our rights adequately
3. 84Patents may not issue from currently pending or future patent applications
4. 85We rely on third-party software to develop our products and significant increases in licensing costs or defects in third-party software could harm our business
5. 86We rely on a variety of intellectual property rights, and if we are unable to maintain or protect our intellectual property, our business and results of operations will be harmed
6. 87We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming, and unsuccessful
7. 88Our commercial success depends significantly on our ability to operate without infringing upon the intellectual property rights of third parties
8. 89relinquish rights associated with one or more of our patent claims if our claims are held invalid or otherwise unenforceable
9. 90If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
10. 91Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products and processes
11. 92Obtaining and maintaining patent protection depend on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
12. 93If our trademarks and trade names are not adequately protected, then, we may not be able to build name recognition in our markets of interest and our business may be adversely affected
13. 94If we cannot show access and copying, then, our copyrights may not provide protection for our software and our business may be adversely affected
14. 95We may not be able to adequately protect our intellectual property rights throughout the world
15. 96We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
16. 97Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time
17. 98Intellectual property rights do not necessarily address all potential threats to our business
18. 99We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
19. 100Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology
20. 101We may not be successful in obtaining necessary intellectual property rights to future products through acquisitions and in-licenses
21. 102Our platform utilizes open-source software, and any failure to comply with the terms of one or more of these open source licenses could negatively affect our business
22. 103Cybersecurity incidents, including data security breaches or computer viruses, could harm our business by disrupting our delivery of services, damaging our reputation, or exposing us to liability
23. 104The regulatory environment governing information, cybersecurity, and privacy is increasingly demanding and continues to evolve
24. 105Any significant interruptions or delays in third-party service and access could result in limited capacity, reduced demand, and loss of customers and adversely affect our business
25. 106Failure to protect our information technology infrastructure against cyber attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results
26. 107disruption of key business operations; and

Risks Related to Regulation of our Industry

1. 108State of New Jersey Department of Health Services legal requirements
2. 109Our future success in part depends on our ability to develop, receive regulatory clearance or approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner
3. 110receive adequate coverage and reimbursement for procedures performed with our products
4. 111gammaCore is subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer
5. 112The laws and regulations to which we are subject are complex and have tended to become more stringent over time. Legislative or regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs, or lower than anticipated sales
6. 113gammaCore is also subject to extensive governmental regulation in foreign jurisdictions, such as Europe, and our failure to comply with applicable requirements could cause our business to suffer
7. 114Once applicable, the MDR may impose increased compliance obligations for us to access the EU market
8. 115For novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device, the FDA may determine that the “de novo” process is the appropriate route to market. The “de novo” process is more costly, time consuming, and uncertain than the traditional 510(k) process
9. 116Modifications to our products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained
10. 117There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products, and failure to obtain necessary clearances or approvals for any such future products would adversely affect our overall ability to grow our business
11. 118In some instances in our advertising and promotion, we may make claims regarding our products relative to competing products, which may subject us to heightened regulatory scrutiny, enforcement risk, and litigation risks
12. 119Our products may in the future be subject to notifications, recalls, or voluntary market withdrawals that could harm our reputation, business and financial results
13. 120We are required to report certain malfunctions, deaths, and serious injuries associated with our products, which can result in voluntary corrective actions or agency enforcement actions
14. 121Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance of our product candidates and to manufacture, market, and distribute our products after clearance is obtained
15. 122We are subject to federal, state, and foreign healthcare laws and regulations, and a finding of failure to comply with such laws and regulations could have a material adverse effect on our business
16. 123the Stark Law, in the event that third-party payors require us to be a durable medical equipment, or DME, supplier or we sell our products directly to providers who are DME suppliers that submit claims to such payors
17. 124Breakthrough Designation from the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of our devices
18. 125Healthcare legislative reform measures may have a material adverse effect on us
19. 126ESG matters, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition, and operating results and may damage our reputation
20. 127Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability

Risks Related to Our Common Stock

1. 128Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock, which could negatively impact the market price and liquidity of our common stock and our ability to access the capital markets
2. 129We are currently subject to securities class action lawsuits against us, which could result in adverse outcomes
3. 130We have broad discretion to determine how to use most of our financial resources and may use them in ways that may not enhance our operating results or the price of our common stock
4. 131An active, liquid and orderly market for our common stock may not continue to be sustained, and our stockholders may not be able to resell their shares at a desired market price and could lose all or part of their investment
5. 132Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
6. 133In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
7. 134Our certificate of incorporation and bylaws provide that we will indemnify our directors and officers to the fullest extent permitted by Delaware law
8. 135We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
9. 136any action asserting a claim against us arising under the DGCL, our certificate of incorporation, or our bylaws; and
10. 137The requirements of being a publicly traded company may strain our resources and divert management’s attention
11. 138Our stock price may be volatile, and you may not be able to resell shares of our common stock at or above the price you paid
12. 139the loss of any of our key scientific or management personnel
13. 140If securities or industry analysts cease publishing regular research or reports about our business or issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
14. 141Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
15. 142Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence control over matters subject to stockholder approval
16. 143Comprehensive U.S. federal income tax reform could adversely affect us
17. 144Our business and stock price could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities